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We used comprehensive serodiagnostic meth-
ods (IgM, IgG, and IgG avidity) and PCR to study 
Merkel cell polyomavirus and trichodysplasia spinulosa- 
associated polyomavirus infections in children observed 
from infancy to adolescence. Comparing seroconver-
sion intervals with previous and subsequent intervals, we 
found that primary infections with these 2 viruses were 
asymptomatic in childhood.
Two novel human polyomaviruses can cause skin diseas-es that are predominant in immunosuppressed persons. 
Merkel cell polyomavirus (MCPyV) is associated with 
Merkel cell carcinoma, which is an uncommon aggressive 
skin cancer, and trichodysplasia spinulosa-associated poly-
omavirus (TSPyV) is associated with trichodysplasia spi-
nulosa, which is a rare skin disorder (1–3). In contrast with 
the rarity of the diseases, serologic studies have shown that 
both of these polyomaviruses infect humans of all ages; 
their seroprevalence has been assessed at 60%–80% among 
adults (4–6). We have reported high rates of MCPyV and 
TSPyV seroconversion among young children, indicating 
that primary exposures to these viruses occur extensively 
in early life (5,7). We observed children from infancy to 13 
years of age by using comprehensive diagnostic methods 
for MCPyV and TSPyV and investigated pediatric primary 
infections with these 2 viruses for clinical correlates.
The Study
This retrospective study was conducted during January 
2011–July 2013 on a subset of a prospective study in which 
children were enrolled at birth and observed until young 
adolescence (8). We observed 144 children born during 
1995–2004, from whom final samples were obtained dur-
ing 2004–2008. 
On average, 13 serum samples per child were obtained 
during the study period (online Technical Appendix Table 
1, wwwnc.cdc.gov/EID/article/20/4/13-1015-Techapp1.
pdf). At each follow-up visit, clinical symptoms or illness-
es since the previous visit were recorded (8). The ethics 
committee of the Hospital District of Southwest Finland 
(www.vsshp.fi/en/) approved the study.
IgG enzyme immunoassays (EIA) for MCPyV and 
TSPyV were conducted as described, except that we omit-
ted subtraction of antigen-free background in the MCPyV 
assay (5,7). The respective lower and higher EIA cutoff 
values for IgG absence and presence were 0.120 and 0.210 
for MCPyV and 0.100 and 0.240 for TSPyV (5,7). IgM 
EIAs for these 2 human polyomaviruses were developed 
as for human bocavirus 1(HBoV1) (8). The cutoff values 
were 0.207 and 0.260 for MCPyV and 0.194 and 0.240 
for TSPyV. The IgG avidity assays were conducted as for 
HBoV1 (method A [9]). The respective cutoff values for 
low and high avidity were 15% and 25%.
Serum samples obtained during the final examination 
of each child were screened for MCPyV IgG and TSPyV 
IgG. Previous samples had not been tested. The children 
whose final samples lacked virus IgG were considered to be 
IgG negative; those whose final samples showed virus IgG 
were considered to have seroconverted. Each previous se-
rum sample for each child who seroconverted was analyzed 
for IgG and IgM to identify the time period of serocon-
version. Serum samples collected immediately before, at, 
and after the IgG seroconversion were examined for viral 
DNA; the seroconversion sample, the subsequent sample, 
and the final sample were examined for IgG avidity.
Of the 144 children, 45 (31%) showed IgG serocon-
version for MCPyV and 39 (27%) for TSPyV. Before they 
were 1 year of age, 4 children showed IgG seroconversion 
for MCPyV at 0.68–0.94 year of age, 1 child showed se-
roconversion for TSPyV at 0.80 year, and another child 
showed MCPyV IgG, IgM, and low avidity of IgG in 
the first sample, which was collected at 0.63 year (online 
Technical Appendix Table 2). None of these children who 
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seroconverted early in life showed maternal IgG to the 
corresponding virus. Comparing participants at 0–1 year 
of age with those at 9–13 years, the seroprevalence for 
MCPyV caused by acquired infections rose from 3.4% to 
65% and for TSPyV, from 0.7% to 53%. Seroconversions 
for each virus continued throughout the study (Figure).
Of the 45 children who seroconverted for MCPyV, 
28 (62%) showed additional markers of primary infec-
tion at the time of IgG seroconversion: IgM was present 
in 15 (33%), and low avidity of IgG was detected in 23 
(51%). Of the 39 TSPyV–seroconverted children, 32 (82%) 
showed corresponding markers: IgM in 30 (67%) and low 
avidity of IgG in 13 (29%). Samples did not show MCPyV 
viremia at or flanking the seroconversion, and TSPyV vire-
mia was observed at low quantity (<104 copies/mL) in the 
samples of 2 who seroconverted. Except 4 seroconverters 
for MCPyV and 1 for TSPyV, all showed long-term matu-
ration of IgG avidity to the corresponding virus.
Maternal IgG showed in 10 (22%) of the 45 who se-
roconverted for MCPyV and in 12 (31%) of the 39 for 
TSPyV at sampling ages of 0.23–0.62 year; these maternal 
IgGs were no longer discernable at 0.49–1.07 year. After 
the first year of life, the age at seroconversion with either 
virus did not appear to correlate with the presence or ab-
sence of maternal antibodies.
To determine clinical correlates of MCPyV and TSPyV 
primary infections, all infection-related symptoms and ill-
nesses during the seroconversion interval were compared 
with those during the previous or subsequent interval for 
each patient who seroconverted (Table). Infection-related 
symptoms during the seroconversion interval were reported 
for 73% of children who seroconverted for MCPyV and for 
82% of those who seroconverted for TSPyV. The occur-
rences of symptoms, however, were not notably different 
from those during the previous or subsequent intervals. Ex-
anthema was reported in 7 (15.9%) children at the MCPyV 
seroconversion interval and in 1 child in each of the adja-
cent periods (2.2% before, 2.3% after). However, the dif-
ferences were not statistically significant (p = 0.0703).
Conclusions
The seroprevalence of MCPyV and TSPyV among 
children <13 years of age increased because of acquired 
infections, a finding consistent with reports that primary 
infections with these 2 viruses are ubiquitous in childhood 
(5,7). The seroprevalence of these viruses had not reached 
a plateau by the end of study; thus, some infections are ex-
pected to occur later than 13 years of age. We expect that 
some children have become infected with these viruses af-
ter exiting the study.
For both viruses, prevalence of maternal antibodies 
during infancy was high, supporting recent findings by 
Martel-Jantin et al. (10). Although the age of the child at 
seroconversion did not appear to correlate with the pres-
ence of maternal antibodies, these antibodies were absent 
from children who showed viral infection during infancy, 
raising the possibility that maternal immunity may protect 
infants from infection by these viruses. However, the prev-
alence of MCPyV infection among infants was higher than 
that of TSPyV, possibly caused by MCPyV shedding from 
parental skin (10–12).
We did not observe any symptom associated with 
the time of seroconversion for these 2 viruses, which im-
plies that primary exposures to these viruses during child-
hood cause no symptoms. When studying MCPyV infec-
tions in adult men who seroconverted, Tolstov et al. also 
found no clinical associations (13). Their observations and 
ours in the current study of MCPyV and TSPyV support 
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Figure. Seroprevalence related to 
polyomavirus primary infections in 
children in Finland during follow-
up, January 2011–July 2013. 
Seroprevalence was calculated 
by	 the	 formula:	 Seroprevalence	
= (no. seropositive children 
remaining in the study at each 
age category) × 100.
Polyomavirus Infections in Children, Finland
the common notion that the prototypic human PyVs, 
BKPyV and JCPyV, also establish persistence without ini-
tial signs (14,15).
Exanthema, a common sign of skin infection, did 
not appear infrequently during MCPyV seroconversion; 
however, the rate did not reach statistical significance (p 
= 0.0703), which might be related to our limited cohort 
size. We cannot rule out that data for some transient skin- 
related signs may not have been captured during pe-
riodic patient interviews. Last, we do not believe that 
our study represents polyomavirus infections during 
childhood worldwide. Larger studies of more geographi-
cally diverse populations are needed to determine wheth-
er primary infection with MCPyV or TSPyV is always 
asymptomatic.
Although IgM and low-avidity IgG were observed 
in more than half of the seroconversion samples, the fre-
quency of viremia was extremely low, indicating serodi-
agnostics as the strategy of choice in diagnosing primary 
infections with MCPyV and TSPyV. Our study suggests 
that these ubiquitous polyomaviruses circulate silently 
among children.
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Table. Infection-related	signs	and	symptoms	during	MCPyV	and	TSPyV	seroconversions	compared	with	previous	and	subsequent	
intervals for asymptomatic polyomavirus infections in children, Finland, January 2011–July 2013* 
Virus	sign/symptom Interval, no. (%) 
 Previous interval  Subsequent interval 
 No. (%) p value  No. (%) p value 
MCPyV	seroconversion,	n	=	45        
 URTI 14 (31.8)  10 (22.2) 0.4545  18	(41.9) 0.3018 
 LRTI 3 (6.8)  2 (4.4) 1.0000  3 (7.0) 1.0000 
 Fever without RTI 2 (6.8)  2 (4.4) 1.0000  3 (7.0) 0.6250 
 Gastroenteritis 9	(20.5)  9	(20.0) 1.0000  11 (25.6) 0.5488 
 Acute tonsillitis 1 (2.3)  0 ND  1 (2.3) 1.0000 
 Acute otitis media 10 (22.7)  11 (24.4) 1.0000  13 (30.2) 0.6291 
 Acute	conjunctivitis 2 (4.5)  1 (2.2) 1.0000  1 (2.3) 1.0000 
 Exanthema 7	(15.9)  1 (2.2) 0.0703  1 (2.3) 0.0703 
 Acute sinusitis 2 (4.5)  0 ND  1 (2.3) 1.0000 
 Total 32 (72.7)  26 (57.8) 0.2632  31 (72.1) 1.0000 
 No data 1  0 NA  2 NA 
TSPyV	seroconversion,	n	=	39        
 URTI 14	(35.9)  9	(23.1) 0.3593  13 (35.1) 1.0000 
 LRTI 3 (7.7)  3 (7.7) 1.0000  2 (5.4) 1.0000 
 Fever without RTI 2 (5.1)  5 (12.8) 0.3750  4 (10.8) 0.6875 
 Gastroenteritis 10 (25.6)  12 (30.8) 0.7744  5 (13.5) 0.3877 
 Acute tonsillitis 1 (2.6)  1 (2.6) 1.0000  2 (5.4) 1.0000 
 Acute otitis media 8 (20.5)  12 (30.8) 0.3877  8 (21.6) 1.0000 
 Acute	conjunctivitis 4 (10.3)  5 (12.8) 1.0000  3 (8.1) 1.0000 
 Exanthema 2 (5.1)  3 (7.7) 1.0000  1 (2.7) 1.0000 
 Acute sinusitis 3 (7.7)  2 (5.1) 1.0000  2 (5.4) ND 
 Total 32 (82.1)  30	(76.9) 0.7266  30 (81.1) 1.0000 
 No data 0  0 NA  2 NA 
*Liddell	exact	test	was	used;	p<0.05	was	considered	significant.	MCPyV,	Merkel	cell	polyomavirus;	TSPyV,	trichodysplasia	spinulosa-associated 
polyomavirus;	LRTI,	lower	respiratory	tract	infection; URTI,	upper	respiratory	tract	infection;	ND,	no	data;	NA,	not	applicable. 
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